C12Y 113/12013
Oplophorus-luciferin 2-monooxygenase
Official title: Oplophorus-luciferin 2-monooxygenase (1.13.12.13)
C12Y113/12013 (Oplophorus-luciferin 2-monooxygenase) appears on 19 US grants and 39 published applications in this corpus.
Search patents in C12Y- Granted patents
- 19
- Published applications
- 39
- Assignees
- 21
- Inventors
- 88
- Latest grant
- 28 Oct 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2008 | 0 | 1 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 1 | 1 |
| 2015 | 0 | 3 |
| 2016 | 3 | 3 |
| 2017 | 1 | 1 |
| 2018 | 4 | 4 |
| 2019 | 4 | 4 |
| 2020 | 1 | 1 |
| 2021 | 1 | 1 |
| 2022 | 1 | 2 |
| 2023 | 1 | 5 |
| 2024 | 0 | 3 |
| 2025 | 2 | 4 |
| 2026 | 0 | 6 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Bioluminescent single photon bioreactor and performing absolute quantification of light-producing activity by enzymes28 Oct 2025US 12,454,716 B2Government of the United States of America, AS Represented By the Secretary of Commerce
- RNA-regulated fusion proteins and methods of their use19 Aug 2025US 12,391,948 B2Cornell University
- Hippo pathway bioluminescent biosensor14 Feb 2023US 11,579,149 B2Queen's University at Kingston
- Method for synthetic genes8 Mar 2022US 11,268,106 B2Jnc Corporation
- Mutated genes for the catalytic protein of Oplophorus luciferase and use thereof27 Apr 2021US 10,988,741 B2Jnc Corporation
- Genetically engineered cd4 t-cells for in situ synthesis of proteins8 Oct 2026US 2026/0308515 A1SRI International
- Fully genetically encoded nad+protein probe based on resonance energy transfer,and preparation method therefor and use thereof17 Sep 2026US 2026/0275323 A1Shenzhen Institutes of Advanced Technology
- Luminescent detection of ADAMTS1330 Jul 2026US 2026/0218270 A1Enzyre B.V.
- Systems and method for target engagement7 May 2026US 2026/0126438 A1Promega Corporation
- Atp-independent bioluminescent reporter variants to improve in vivo imaging19 Mar 2026US 2026/0077068 A1University of Virginia Patent Foundation
Most cited
By later US patents
- Process for production of recombinant proteins as a soluble form7US 8,853,374 B2Jnc Corporation · 2014
- Coelenterazine analogues3US 10,000,500 B2Promega Corporation · 2018
- Coelenterazine analogues2US 10,428,075 B2Promega Corporation · 2019
- Process for production of recombinant proteins as a soluble form2US 9,738,692 B2Jnc Corporation · 2017